Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)

被引：0
|
作者：
Chen, Jinzhang
Zang, Mengya
Pang, Huajin
Li, Chuanjiang
Zhao, Jianbo
Guo, Yabing
Hou, Jinlin
机构：
[1] Southern Med Univ, Hepatol Unit, Nanfang Hosp, Guangzhou, Peoples R China
[2] Southern Med Univ, Dept Infect Dis, Nanfang Hosp, Guangzhou, Peoples R China
[3] Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China
[4] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, State Key Lab Organ Failure Res,Guangdong Prov Ke, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
中国国家自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16128
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol
    Maohui Chen
    Yizhou Huang
    Shuliang Zhang
    Taidui Zeng
    Guanglei Huang
    Chun Chen
    Bin Zheng
    Trials, 24 (1)
  • [42] Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol
    Chen, Maohui
    Huang, Yizhou
    Zhang, Shuliang
    Zeng, Taidui
    Huang, Guanglei
    Chen, Chun
    Zheng, Bin
    TRIALS, 2023, 24 (01)
  • [43] A prospective, single-arm, phase II clinical study of tislelizumab in combination with lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with high risk of recurrence.
    Song, Tianqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial
    Chen, Jing
    Han, Yingyan
    Hu, Yingjie
    Feng, Xue
    Meng, Xiaolin
    Guo, Shuaiqingying
    Sun, Chaoyang
    Chen, Gang
    Li, Kezhen
    BMJ OPEN, 2023, 13 (05):
  • [45] Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: A phase II, single-arm, prospective study
    Chen, Shiguang
    Zhang, Kongzhi
    Liu, Weifu
    Yu, Wenchang
    EUROPEAN JOURNAL OF CANCER, 2020, 134 : 90 - 98
  • [46] Perioperative lenvatinib combined with tislelizumab plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence: A prospective, single-arm, phase 2 trial.
    Wu, Jia-Yi
    Fu, Yang-Kai
    Wen, Tianfu
    Wang, Shuang-Jia
    Chen, Jiafei
    Zhang, Zhibo
    Liu, Chongyuan
    Wang, Wei
    Fang, Lu
    Tang, Zhong
    Chen, Yufeng
    Yan, Maolin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 503 - 503
  • [47] The efficacy and safety of toripalimab combined with sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study.
    Yang, Xin-Rong
    Cheng, Jian-Wen
    Wu, Suiyi
    Hu, Bo
    Qiu, Shuang-Jian
    Sun, Hui-Chuan
    Fan, Jia
    Zhou, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] TACE combined with tislelizumab and TKI as a conversion therapy in initial unresectable hepatocellular carcinoma (uHCC): A prospective single-arm phase II clinical study
    Liu, S.
    Lin, S.
    Luo, H.
    Luo, J.
    Mo, W.
    Zhong, J-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S78 - S79
  • [49] A Phase 2, Prospective, Multicenter, Single-arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-stage Hepatocellular Carcinoma: TACTICS-L Trial
    Kudo, Masatoshi
    Ueshima, Kazuomi
    Saeki, Issei
    Ishikawa, Toru
    Inaba, Yoshitaka
    Morimoto, Naoki
    Aikata, Hiroshi
    Tanabe, Nobukazu
    Wada, Yoshiyuki
    Kondo, Yasuteru
    Tsuda, Masahiro
    Nakao, Kazuhiko
    Ito, Takanori
    Hosaka, Tetsuya
    Kawamura, Yusuke
    Kuzuya, Teiji
    Nojiri, Shunsuke
    Ogawa, Chikara
    Koga, Hironori
    Hino, Keisuke
    Ikeda, Masafumi
    Moriguchi, Michihisa
    Hisai, Takashi
    Yoshimura, Kenichi
    Furuse, Junji
    Arai, Yasuaki
    LIVER CANCER, 2024, 13 (01) : 99 - 112
  • [50] Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
    Xia, Yongxiang
    Tang, Weiwei
    Qian, Xiaofeng
    Li, Xiangcheng
    Cheng, Feng
    Wang, Ke
    Zhang, Feng
    Zhang, Chuanyong
    Li, Donghua
    Song, Jinhua
    Zhang, Hui
    Zhao, Jie
    Yao, Aihua
    Wu, Xiaofeng
    Wu, Chen
    Ji, Guwei
    Liu, Xisheng
    Zhu, Feipeng
    Qin, Lang
    Xiao, Xuan
    Deng, Zhenhua
    Kong, Xiangyi
    Li, Si
    Yu, Yangyang
    Xi, Wenjing
    Deng, Wanglong
    Qi, Chuang
    Liu, Hanyuan
    Pu, Liyong
    Wang, Ping
    Wang, Xuehao
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (04)
12345